Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Authors

Junyi Shen

Published

June 20, 2024

Abstract

The FDA's alerts regarding the T-cell lymphoma risk post CAR-T therapy has garnered global attention, yet a comprehensive profile of second primary malignancies (SPMs) following CAR-T treatment is lacking.

Supporters

Support the authors with ResearchCoin

Journal

EClinicalMedicine

Topics

DOI

10.1016/j.eclinm.2024.102684

License

CC-BY-NC-ND

Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Authors

Junyi Shen

Published

June 20, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

EClinicalMedicine

Topics

DOI

10.1016/j.eclinm.2024.102684

License

CC-BY-NC-ND

Paper

Paper

Paper

Paper

Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Abstract

Supporters

Journal

Topics

DOI

License

Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Abstract

Supporters

Journal

Topics

DOI

License

Supporters

Journal

Topics

DOI

License